Trials / Recruiting
RecruitingNCT06760455
A Safety and Tolerability Study of BPR-30221616 Injection in Healthy Subjects
A Single-center, Double-blind, Placebo-controlled, Dose-escalation Phase I Clinical Study to Evaluate the Safety and Tolerability of BPR-30221616 Injection in Healthy Subjects
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- Chengdu Brilliant Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine the safety, tolerability, pharmacokinetics、 pharmacodynamics and immunogenicity of BPR-30221616 in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BPR-30221616 Injection | BPR-30221616 will be administered by subcutaneous (SC) injection |
| DRUG | Sodium Chloride Injection | Sodium Chloride Injection will be administered by SC injection |
Timeline
- Start date
- 2025-01-10
- Primary completion
- 2026-01-24
- Completion
- 2026-12-05
- First posted
- 2025-01-06
- Last updated
- 2025-02-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06760455. Inclusion in this directory is not an endorsement.